Followers | 260 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |
Saturday, February 22, 2014 1:23:45 PM
Dr Eva Harris, Professor, Division of Infectious Diseases and Vaccinology; Director, Center for Global Public Health
Research Description:
Dr. Harris has developed a multidisciplinary approach to study the molecular virology, pathogenesis, immunology, and epidemiology of dengue, the most prevalent mosquito-borne viral disease in humans. Her work investigates the mechanism of dengue virus translation and replication and host cell-virus interactions, as well as viral and host factors that modulate disease severity. One major research focus has been the development of a mouse model to study viral tropism and pathogenesis, investigate the immune response to dengue virus infection, and generate a better model of disease. This has resulted in a mouse model for antibody-dependent enhancement of dengue disease that is being used to dissect antibody determinants of protection, enhancement, and therapeutic efficacy and to test different classes of candidate antiviral compounds. Her field work focuses on laboratory-based and epidemiological studies of dengue and influenza in endemic Latin American countries.
Results of Initial Results Dengue Hemorrhagic Fever Treated with nanoviricide injection alone:
Results of the study demonstrated a 50 percent survival rate of the animals in the ADE model; additionally, the length of survival of animals treated with several Dengue nanoviricides surpassed the length of survival for animals treated with the vehicle alone.
“We are very excited about these results,” Dr. Harris stated. “This is a very important demonstration of a viable drug candidate leading to significant survival in the ADE model of Dengue virus infection. I believe nanoviricides show great promise in our model and against severe dengue disease.”
Recent NNVC News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/27/2024 08:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM